UBS AM
GMAB icon

UBS AM’s Genmab GMAB Stock Holding History

UBS AM’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$896K Sell
32,612
-32
-0.1% -$850 ﹤0.01% 2377
2026
Q1 		$876K Buy
32,644
+26,548
+435% +$796K ﹤0.01% 2387
2025
Q4 		$188K Buy
+6,096
New +$190K ﹤0.01% 2466
2024
Q2 		– Sell
-85,200
Closed -$2.55M – 2838
2024
Q1 		$2.55M Buy
+85,200
New +$2.5M ﹤0.01% 1559
2019
Q4 		– Sell
-241,703
Closed -$4.9M – 2642
2019
Q3 		$4.9M Buy
+241,703
New +$4.76M ﹤0.01% 1210

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS AM's GMAB Position: Q2 2026 in Review

UBS AM reduced its Genmab (GMAB) stake by 0.1% in Q2 2026, selling an estimated $850 and leaving 32,612 shares worth $896K. The position accounts for ﹤0.01% of the portfolio, ranked #2377.

UBS AM first reported a position in GMAB in Q3 2019 and has held it in 5 quarters since. The position peaked at $4.9M in Q3 2019. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • UBS AM held 32,612 shares of Genmab worth $896K as of Q2 2026.
  • UBS AM sold 32 Genmab shares in Q2 2026, an estimated $850.
  • Genmab made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2377 holding.
  • UBS AM first reported a position in Genmab in Q3 2019 and has held it in 5 quarters since.
  • UBS AM's Genmab position peaked at $4.9M in Q3 2019.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.